Navigation Links
Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
Date:3/23/2011

ures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and th
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
2. Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
3. AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation
4. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
5. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
6. Los Angeles Dentist, Dr. Kevin Sands, Uses the Latest Technologies to Provide VIP Services and Treatments for His Patients
7. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
8. Practice Guidelines Confirm Utility of Endoscopic Radiofrequency Ablation (RFA) for the Treatment of Barretts Esophagus
9. Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act of 2011
10. Tris Announces NDA Acceptance of Extended Release Carbinoxamine Oral Suspension for the Treatment of Allergies in Kids Two Years and Older
11. Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
(Date:7/27/2014)... July 27, 2014 The European Agricultural ... in Europe with analysis and forecast of revenue. The ... from around $509.4 million in 2013 to $657.1 million ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
(Date:7/27/2014)... 27, 2014 Metachromatic leukodystrophy (MLD, ... storage disease which is commonly listed in the ... sphingolipidoses as it affects the metabolism of sphingolipids. ... the fatty covering which acts as an insulator ... nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 One of the ... genomics products from the Asia Pacific (APAC) region. The Diagnostics ... to generate high demand for genomics solutions, thereby contributing to ... will grow at a CAGR of 11.21 percent over ... driver of the market is an increase in the demand ...
(Date:7/27/2014)... 2014 Alta Resources , a ... for Fortune 500 brands, announced today that it plans ... in Wisconsin, California, Florida and the Philippines. , A ... clients, which have seasonal ramp-ups that require additional staffing ... 2014 through February 2015. As more consumers become eligible ...
(Date:7/27/2014)... 27, 2014 Wright & Schulte LLC ... filed a GranuFlo lawsuit against Fresenius Medical Care ... over the recalled dialysis drugs GranuFlo and NaturaLyte. The ... by not disclosing the heart attack risks associated with ... Fresenius notified its own clinics, practitioners and physicians about ...
Breaking Medicine News(10 mins):Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 2Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 3Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 5Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 2Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 4Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 5
... of Chemicals, has shifted the burden or responsibility of handling ... would be bound by law to make use of only ... law aims to make chemicals used in all products ; ... ,The European Parliament has approved this legislation on ...
... plausible culprit for rendering sick nearly 260 Tewksbury students, ... stomach virus// has allegedly gripped several of the students ... not about to spare anyone- teachers, parents and siblings ... us to keep everything clean,” said Sue McLaughlin, co-chairwoman ...
... for ovarian cancer are at increased risk of a ... have high// levels of a binding protein that triggers ... of malignancy. ,“Now there’s the possibility that ... surgery might identify women most at risk for recurrence ...
... symptoms, including enlarged or painful breast tissue, but the ... Mayo Clinic Cancer Center. // Mammograms are used to ... very rare in males. ,Their study, presented Saturday, ... Antonio Breast Cancer Symposium, suggests physicians should reconsider ordering ...
... vaccine against HIV/AIDS, the 'social vaccine' of mass awareness needs ... a top UN official here said Saturday. // ... HIV/AIDS," said Peter Piot, executive director of United Nations Programme ... create a mass awareness to educate the people about the ...
... followed the discovery of neural stem cells and their potential ... spinal cord//, recent research identified “cancer stem cells,” a small ... cells comprising a malignant brain tumor. Theoretically, if these mother ... to sustain itself. On the other hand, if these cells ...
Cached Medicine News:Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2Health News:Use of Mammograms in Men 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3
The Deluxe Knee Immobilizer provides superb lightweight immobilization following injury or surgery. It is available in a wide array of sizes for excellent comfort and fit....
... and Defiance III is DonJoy's hallmark knee ... and design, this lightweight brace provides durable ... MCL and LCL instabilities. Plus, the low-profile ... uniforms, including hockey and football. As the ...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Dynamic brace that provides a low load, prolonged stretch to the connective tissue around the joint using an adjustment hinge with a built-in tension spring...
Medicine Products: